Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005.  He focuses novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies.   

Previously, Bruce was a Principal at Caxton Health Holdings L.L.C., where he focused on the firm’s private equity activities, ranging from early stage venture capital through late stage private equity. Prior to Caxton, he was an Associate Principal at McKinsey & Company, where he advised biopharmaceutical clients on R&D productivity, corporate strategy and business development issues.

Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, and Zafgen.  He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail, Sept 2008), Proprius (acquired by Cypress Biosciences, Feb 2008), and Stromedix..

As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University’s Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine.  His research focused on immune surveillance, and how the immune system responds to intracellular pathogenesis.  Prior to graduate studies, he worked on President Clinton’s Domestic Policy Council in the National Office of AIDS Policy. He received his Bachelor of Science degree summa cum laude in Biochemistry from the Pennsylvania State University.  

He serves as a Trustee of the New York Academy of Medicine, where he participates on the Executive Committee as Treasurer and helps manage the Academy’s Endowment.  He also currently serves in several life science advisory roles, including UCB Pharma NewMedicines Science Advisory Board, Beth Israel Deaconess Medical Center’s Accelerating Bench to Bedside effort, and LifeTech Boston seed-stage loan program.  Bruce has also authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology and Nature Reviews Drug Discovery.